Eloxx Pharmaceuticals Company Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of RNA-modulating drugs in the United States.
The company develops ELX-02, which is in phase II clinical trial for the treatment of nonsense mutation alport syndrome; ZKN013, which is in investigation phase for the treatment of nonsense mutation recessive dystrophic and junctional epidermolysis bullosa; and ZKN013, which is in investigation phase for the treatment of nonsense mutation familial adenomatous polyposis.
It also offers platform technologies, including Turbo-ZM and Ribosome Modulating Agents; and Eukaryotic Ribosomal Selective Glycosides for the treatment of rare and ultra-rare premature stop codon diseases.
The company is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Sumit Aggarwal |
Contact Details
Address: 480 Arsenal Way Watertown, Massachusetts 02472 United States | |
| Phone | 781 577 5300 |
| Website | eloxxpharma.com |
Stock Details
| Ticker Symbol | ELOX |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US29014R1032 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sumit Aggarwal M.B.A. | President, Chief Executive Officer and Director |
| Daniel E. Geffken M.B.A. | Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Barbara A. Ryan | Investor Relations Officer |
| Dr. Ali Hariri M.D. | Chief Medical Officer |